Janus Henderson Discloses 6.00% Stake in Compass Therapeutics
Ticker: CMPX · Form: SC 13G · Filed: Feb 1, 2024 · CIK: 1738021
| Field | Detail |
|---|---|
| Company | Compass Therapeutics, Inc. (CMPX) |
| Form Type | SC 13G |
| Filed Date | Feb 1, 2024 |
| Risk Level | low |
| Sentiment | bullish |
Complexity: simple
Sentiment: bullish
Topics: institutional-ownership, passive-investment, biotech
TL;DR
**Janus Henderson just revealed a 6% stake in Compass Therapeutics, signaling institutional confidence.**
AI Summary
Janus Henderson Group plc, a major investment firm, has disclosed that it owns 6.00% of Compass Therapeutics, Inc.'s Common Stock as of January 22, 2024. This filing, an SC 13G, indicates that Janus Henderson is a significant passive investor in Compass Therapeutics, a biotechnology company. This matters to current and potential investors because a large institutional holding can signal confidence in the company's future, potentially influencing stock stability and investor sentiment.
Why It Matters
A substantial institutional stake like this can provide a vote of confidence in Compass Therapeutics, potentially attracting other investors and stabilizing the stock price.
Risk Assessment
Risk Level: low — This filing indicates a passive investment by a large institution, which generally reduces perceived risk for the underlying stock.
Analyst Insight
A smart investor would view this as a positive signal, suggesting institutional confidence in Compass Therapeutics, and might consider further research into the company's fundamentals and pipeline.
Key Numbers
- 6.00% — Ownership Percentage (Janus Henderson Group plc's stake in Compass Therapeutics, Inc.)
Key Players & Entities
- Janus Henderson Group plc (company) — the reporting person and institutional investor
- Compass Therapeutics, Inc. (company) — the subject company whose stock is being reported
- 6.00% (dollar_amount) — the percentage of Common Stock owned by Janus Henderson
- January 22, 2024 (date) — the date of the event requiring the filing
Forward-Looking Statements
- Compass Therapeutics' stock may experience increased stability due to institutional backing. (Compass Therapeutics, Inc.) — medium confidence, target: Next 6-12 months
FAQ
What type of filing is this document?
This document is an SC 13G filing, specifically an initial filing (Amendment No.: 0*) under Rule 13d-1(b) and Rule 13d-1(c) of the Securities Exchange Act of 1934.
Who is the reporting person in this SC 13G filing?
The reporting person is Janus Henderson Group plc, an investment advice company with its business address in London, X0 EC2M 3AE.
Which company's stock is the subject of this filing?
The subject company is Compass Therapeutics, Inc., a biological products company located at 80 Guest Street, Boston, MA 02135.
What percentage of Compass Therapeutics, Inc.'s Common Stock does Janus Henderson Group plc own?
Janus Henderson Group plc owns 6.00% of Compass Therapeutics, Inc.'s Common Stock, as stated in the filing: "JANUS HENDERSON GROUP PLC OWNS 6.00% OF COMPASS THERAPEUTICS, INC."
What was the date of the event that triggered this filing?
The date of the event which required the filing of this statement was January 22, 2024, as indicated in the filing under "Date of Event Which Requires Filing of this Statement: 1/22/2024."
Filing Details
This Form SC 13G (Form SC 13G) was filed with the SEC on February 1, 2024 regarding Compass Therapeutics, Inc. (CMPX).